BioAI 相变：蛋白设计从模型演示走向药企工作流

Protein design is shifting from an impressive research capability into a product that major pharmaceutical companies can buy and use.

Co-folding models can reason about interacting proteins together instead of predicting each structure in isolation.

Generative protein models create value only when computational proposals are tested through a fast and reliable laboratory validation loop.

Antibodies are attractive design targets because biology already provides machinery for recognition, binding, and therapeutic action.

Once prediction accuracy crosses a practical threshold, pharmaceutical teams begin reorganizing workflows around the model.

A strong foundation model does not automatically solve enterprise workflows such as selectivity, cross-reactivity, and bispecific design.

As protein design becomes crowded, proprietary validation data and workflow depth matter more than merely offering another model.

Large pharmaceutical companies behave like sophisticated capital allocators that manage portfolios of risky scientific bets.

The funding model may be a larger constraint on biopharma progress than the availability of promising scientific ideas.

The field needs builders who can combine software engineering, biological intuition, and experimental discipline.